



Universiteit
Leiden
The Netherlands

Lipids, inflammation and atherosclerosis

Stitzinger, M.

Citation

Stitzinger, M. (2007, February 1). *Lipids, inflammation and atherosclerosis*.
Retrieved from <https://hdl.handle.net/1887/9729>

Version: Not Applicable (or Unknown)

License:

Downloaded from: <https://hdl.handle.net/1887/9729>

Note: To cite this publication please use the final published version (if applicable).

Chapter 3

INTERLEUKIN-9 INHIBITS β -VLDL INDUCED FOAM CELL FORMATION BY REDUCING RECEPTOR EXPRESSION IN MURINE MACROPHAGES

Miranda Stitzinger¹, Menno Hoekstra¹, Jacques van Snick², Theo J.C. van Berkel¹ and Johan Kuiper¹

¹Division of Biopharmaceutics, LACDR, Leiden University, The Netherlands

²Ludwig Institute for Cancer Research, Brussels, Belgium

Submitted for publication

ABSTRACT

Previously, we found that treatment of LDLr deficient mice with IL-9 resulted in inhibition of atherosclerosis. To unravel the underlying mechanism of the atheroprotective effect of IL-9, we investigated the effect of IL-9 on murine macrophage RAW 264.7 cells loaded with β -VLDL. IL-9 inhibited β -VLDL induced foam cell formation of RAW cells with 50%. Quantitative real-time PCR-analysis showed that IL-9 caused a 1.28-fold reduction in the mRNA expression of the LDLr, a 2.13-fold reduction in LRP-1 and a 1.89-fold reduction in SR-BI, all tentative receptors for β -VLDL uptake. Experiments with [³H]cholesterol loaded cells revealed that the reduction in foam cell formation was not due to a stimulatory effect of IL-9 on cholesterol efflux. In line with these results, IL-9 did not affect mRNA expression levels of the cholesterol efflux pumps ABCA1 and ABCG1. The mRNA expression of PPAR α , a nuclear receptor whose activation leads to inhibition of foam cell formation, was increased 4.00-fold by IL-9. In addition, IL-9 caused a 1.75-fold and 2.08-fold reduction in the expression of SREBP-1 and SREBP-2, transcription factors involved in intracellular cholesterol homeostasis. The reduction in lipoprotein uptake receptors, the activation of the nuclear receptors PPAR α and the reduction of the transcription factors SREBP-1 and SREBP-2 by IL-9 will all contribute to the protective effect of IL-9 in atherosclerosis in a coordinated way.

INTRODUCTION

Interleukin (IL)-9 is a pleiotropic cytokine that was first described as a T cell growth factor¹, but IL-9 also affects many other cells including mast cells, erythroid precursors, B lymphocytes, eosinophils, bronchial epithelial cells, neuronal precursors and macrophages^{2,3}. IL-9 was primarily identified as a risk factor for asthma⁴ and transgenic mice overexpressing IL-9 present features of asthma^{5,6}. The treatment of mice with an IL-9 neutralizing antibody inhibits the development of allergic pulmonary inflammation and airway hyperresponsiveness^{7,8}. In contrast, a T-helper (Th)2 response to allergen after sensitization is still present in IL-9 deficient mice as well as other features of asthma⁹. In addition, IL-9 is a susceptibility factor in *Leishmania major* infection¹⁰ and leads to an early death in mice with chronic *Schistosoma mansoni* infection¹¹ by inducing a Th2 response.

On the other hand, several studies show that IL-9 may exhibit protective effects by inhibiting inflammatory responses. IL-9 shows these anti-inflammatory effects in the protection of mice from Gram-negative bacterial shock by suppression of tumor necrosis factor (TNF)- α , IL-12, and interferon (IFN)- γ , and induction of IL-10¹². Other studies revealed a protective role of IL-9 in the host immunity to intestinal nematode infections^{13,14}. IL-9 may directly deactivate lipopolysaccharide (LPS) stimulated blood mononuclear phagocytes and the mechanism of inhibition involves the increased transforming growth factor (TGF) β 1 production by these cells¹⁵. In a recent study¹⁶, we investigated the role of IL-9 in atherosclerosis, a disease characterized by chronic inflammation¹⁷ and affected by pro- and anti-inflammatory mediators¹⁸. Treating low-density lipoprotein (LDL) receptor (LDLr) deficient mice with IL-9 led to a more than 60% reduction in atherosclerotic lesion development. Moreover, functional blocking of endogenous IL-9 resulted in an increase in atherosclerosis¹⁶. IL-9 not only affected the production of pro-inflammatory cytokines but also reduced the *in vitro* adhesion of monocytes to endothelial cells.

In the early stages of atherosclerosis, circulating monocytes infiltrate the vessel wall in response to the enhanced expression of adhesion molecules and chemoattractants in activated endothelial cells. The infiltrated monocytes differentiate into macrophages and, activated by inflammatory stimuli, synthesize and secrete various bioactive molecules, including cytokines, growth factors, and proteases. As a result of excessive accumulation of cholesteryl esters from modified lipoproteins, macrophages transform into foam cells, which have a prominent role in the initiation and progression of the atherosclerotic plaque¹⁷⁻²⁰.

Foam cells can be formed *in vitro* by receptor mediated uptake of either β -very low-density lipoprotein (β -VLDL)²¹ or experimentally modified lipoproteins such as acetylated LDL (acLDL)²² and oxidized LDL (oxLDL)²³. In addition to the uptake of modified lipoproteins, cholesterol efflux is an important process in the development of foam cells, because foam cell formation is the result of an imbalance in cholesterol homeostasis²⁰. ATP-binding cassette (ABC)G1²⁴⁻²⁶ and ABCA1^{27,28} are the key mediators of cholesterol efflux to high-density lipoprotein (HDL) and apolipoprotein (apo)A-I, respectively. Also scavenger receptor class B, type I (SR-BI) is able to facilitate cholesterol efflux to HDL²⁹.

Various mediators can affect foam cell formation. Nuclear receptors such as peroxisome proliferator-activated receptor (PPAR) α and PPAR γ inhibit foam cell formation, but PPAR δ does not influence foam cell formation³⁰. In addition, many inflammatory mediators influence foam cell formation. Most studies suggest a foam cell inducing effect of pro-inflammatory mediators such as LPS and TNF- α ^{31,32} and a suppressive effect of anti-inflammatory mediators such as TGF β 1^{33,34}. In contrast, the anti-inflammatory IL-10 enhances oxLDL induced foam cell formation of macrophages by anti-apoptotic mechanisms³⁵.

In the present study, we show that the anti-inflammatory cytokine IL-9 inhibited β -VLDL induced foam cell formation in RAW 264.7 murine macrophage cells. IL-9 reduced the expression of receptors for β -VLDL, whereas cholesterol efflux was not affected. Our data provide the first evidence for a direct effect of IL-9 on the gene expression of key players in foam cell formation, which may contribute to the anti-atherogenic effect of IL-9.

MATERIALS AND METHODS

Cell culture

RAW 264.7 murine macrophage cells were cultured in complete medium containing DMEM supplemented with 10% fetal bovine serum, 100 IU/ml penicillin and 100 μ g/ml streptomycin (P/S) and 4 mM L-glutamine (all from BioWittakerTM) at 37°C in an humidified atmosphere with 5% CO₂.

Isolation of β -VLDL

β -VLDL was obtained from rats fed a RMH-B diet containing 2% cholesterol, 5% olive oil, and 0.5% cholic acid for 2 weeks (Abdiets). The rats were fasted overnight and anesthetized after which blood was collected by puncture of the abdominal aorta. Serum was centrifuged at 40,000 rpm in a discontinuous KBr gradient for 18 hours as reported earlier³⁶. β -VLDL was collected and dialysed against phosphate buffered saline containing 1 mM EDTA. Isolated β -VLDL was characterized as described by Van Eck *et al*³⁷. Animal experiments were performed at the Gorlaeus Laboratories of the Leiden/Amsterdam Center for Drug Research in accordance with the national laws. The Ethics Committee for Animal Experiments of Leiden University approved all experimental protocols.

Foam cell formation

RAW cells (0.75×10^5) were seeded in 24-well plates for 2 hours. Non-adherent cells were removed and adherent cells were cultured for 16 hours in absence or presence of 40 ng/ml recombinant murine IL-9 purified from baculovirus-infected Sf9 insect cell cultures³⁸. Cells were incubated with β -VLDL (25-100 μ g/ml) for 24 hours. The cells were stained for lipid accumulation with oil red O (Sigma) and photographed using a Leica DMRE microscope (1000x magnification) coupled to a video camera. Leica Qwin Imaging software (Leica Ltd.) was used to quantify foam cell formation by calculating the area of oil red O staining compared to the total cell area.

Cholesterol efflux

To study cholesterol efflux, RAW cells (0.25×10^5) were seeded in 24-well plates in complete medium. After 2 hours, non-adherent cells were removed and adherent cells were loaded with $0.5 \mu\text{Ci/ml}$ ^3H -cholesterol (Amersham) in DMEM supplemented with 2% fatty acid free BSA (Sigma), P/S and L-glutamine (DMEM/2%BSA) for 24 hours at 37°C . Subsequently, cells were cultured in DMEM/2%BSA in presence or absence of IL-9 for 24 hours. Cholesterol efflux was studied by incubation of the cells with DMEM/2%BSA alone (negative control) or supplemented with either $5 \mu\text{g/ml}$ apoA-I (ABCA1-mediated) or $100 \mu\text{g/ml}$ HDL (ABCG1-mediated) for 24 hours. Radioactivity of media and lysed cells was determined with a Tri-Carb 2900TR liquid scintillation analyser (Packard) using Packard QuantaSmart software. Cholesterol efflux was defined as radioactivity in media compared to radioactivity in both media and cells.

Gene expression

RAW cells (1.5×10^5) were seeded in 24-well plates for 2 hours. Non-adherent cells were removed and adherent cells were cultured for 16 hours in absence or presence of 40 ng/ml IL-9. Quantitative gene expression analysis on these cells was performed as described³⁹. In short, total RNA was isolated using TriZol[®] reagent (Invitrogen Life technologies) according to the manufacturer's instructions and reverse transcribed using RevertAid[™] reverse transcriptase. Gene expression analysis was performed using real-time SYBR Green technology (Eurogentec) with the primers displayed in **Table 1**. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), acidic ribosomal phosphoprotein P0 (36B4) and hypoxanthine-guanine phosphoribosyltransferase (HPRT) were used as standard housekeeping genes. Relative gene expression numbers were calculated by subtracting the threshold cycle number (Ct) of the target gene from the average Ct of housekeeping genes and raising 2 to the power of this difference. The average Ct of three housekeeping genes was used to exclude that changes in the relative expression were caused by variations in the separate housekeeping gene expressions. The average Ct values for housekeeping genes (mean $\pm$ SEM; n=6) were 17.1 ± 0.2 for control cells and 17.0 ± 0.2 for IL-9 treated cells.

Table 1: Primers for quantitative real-time PCR analysis

Gene	GenBank Accession	Forward primer	Reverse Primer
36B4	X15267	GGACCCGAGAAGACCTCCTT	GCACATCACTCAGAATTTCAATGG
ABCA1	NM013454	GGTTTGGAGATGTTTATACAATAGTTGT	TTCCCGAAACGCAAGTC
ABCG1	NM009593	AGGTCTCAGCCTTCTAAAGTTCCTC	TCTCTCGAAGTGAATGAAATTTATCG
GADPH	NM008084	TCCATGACAACTTTGGCATTG	TCACGCCACAGCTTTCCA
HPRT	J00423	TTGCTCGAGATGTCATGAAGGA	AGCAGGTCAGCAAAGAACTATAG
LDLr	Z19521	CTGTGGGCTCCATAGGCTATCT	GCGGTCCAGGGTCATCTTC
LRP-1	NM008512	TGGGTCTCCGAAATCTGTT	ACCACCGCATTTCTGAAGGA
PPAR α	NM011144	TGAACAAAGACGGGATG	TCAAACCTTGGGTTCCATGAT
PPAR γ	NM011146	CATGCTTGTGAAGGATGCAAG	TTCTGAAACCGACAGTACTGACAT
PPAR δ	NM011145	GAGGGGTGCAAGGGCTTCTT	CACTTGTTGCGGTTCTTCTTCTG
SR-BI	NM016741	GGCTGCTGTTTGCTGCG	GCTGCTTGATGAGGGAGGG
SREBP-1	AB017337	GACCTGGTGGTGGGCACTGA	AAGCGGATGTAGTCGATGGC
SREBP-2	AF374267	TGAAGCTGGCCAATCAGAAAA	ACATCACTGTCCACCAGACTGC
TGF β 1	NM011577	AGGGCTACCATGCCAATTCT	GCAAGGACCTTGCTGTACTGTGT
VLDLr	NM013703	GGCTCTGGCGAGTGCATT	GCCGTCCTTGCACTCAGG

Immunoblotting

RAW cells (3.0×10^5) were seeded in a 6 well-plate, after which they were treated with IL-9 and β -VLDL as described above. Subsequently, cells were washed with ice-cold PBS and lysed in 50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% deoxycholate, 1% SDS containing 0.02 μ g/ml leupeptin, 0.02 μ g/ml aprotinin, and 0.02 μ g/ml trypsin inhibitor. Cell debris was removed by centrifugation at 10,000 rpm for 10 min. Equal amounts of protein (25 μ g) were separated on 7.5% SDS-PAGE gels and electrophoretically transferred to Protran nitrocellulose membrane (Schleicher & Schnell). Immunolabeling was performed using rabbit polyclonal antibodies against SR-BI (amino acids 496-509, Abcam), SREBP-1 (amino acids 41-200, Santa Cruz Biotechnology) and SREBP-2 (amino acids 812-975, Santa Cruz Biotechnologies) as primary antibodies. Goat-anti-rabbit IgG (Jackson ImmunoResearch) was used as secondary antibody. Finally, immunolabeling was detected by enhanced chemiluminescence (ECL plus, Amersham Biosciences), scanned by a Typhoon 9400 variable mode imager (Amersham Pharmacia Biotech) and analysed using ImageQuant™ software (Amersham Pharmacia Biotech).

RESULTS

Foam cell formation

Macrophage foam cell formation *in vitro* requires the uptake of modified lipoproteins such as oxLDL²³ or acLDL²². β -VLDL, a lipoprotein present in the plasma of cholesterol-rich fed animals⁴⁰, is also capable of inducing foam cell formation²¹. To induce foam cell formation, RAW 264.7 cells were incubated with β -VLDL (25-100 μ g/ml) for 24 hours. The induction of foam cell formation by incubating RAW 264.7 cells with β -VLDL was clearly visible (**Fig. 1A**) and the lipid area of cells incubated with 25, 50 and 100 μ g/ml β -VLDL was 2.3%, 4.4% and 9.5% of the total cell area respectively (**Fig. 1C**).




Fig. 1: Effect of IL-9 on β -VLDL induced foam cell formation. RAW cells were cultured for 16 hours in the absence (**A**) or presence (**B**) of IL-9 and subsequently incubated with 50 μ g/ml β -VLDL for 24 hours. The cells were stained for lipid accumulation with oil red O and photographed. **C** RAW cells were cultured in the absence or presence of IL-9 for 16 hours, after which they were incubated with β -VLDL for 24 hours. Oil red O staining was quantified using Leica Qwin Imaging software. Values are expressed as mean $\pm$ SEM of % lipid area compared to total cell area. Significant differences between control cells and cells pre-treated with IL-9: * $p < 0.05$, *** $p < 0.001$. Significant differences between control cells incubated with 25 μ g/ml β -VLDL and control cells incubated with 50 or 100 μ g/ml: ## $p < 0.01$ and ### $p < 0.001$.

Since foam cell formation is affected by pro- and anti-inflammatory mediators, we studied the effect of IL-9, an anti-inflammatory cytokine, by incubating RAW cells with 40 ng/ml IL-9 for 16 hours prior to incubation with β -VLDL (**Fig. 1B**). After incubation with 25, 50 and 100 μ g/ml β -VLDL for 24 hours, the lipid area of IL-9 pre-treated cells was 1.1%, 2.3% and 4.5% of the total cell area, respectively (**Fig. 1C**). Compared to the lipid area of control cells after incubation with β -VLDL between 25 and 100 μ g/ml, a significant 2-fold reduction ($p < 0.01$) in β -VLDL induced foam cell formation was observed after IL-9 treatment.

Receptors for β -VLDL

The major route for β -VLDL uptake by macrophages is the LDLr⁴¹. In addition, the VLDL receptor (VLDLr)⁴², LDLr related protein-1 (LRP-1)⁴³ and SR-BI⁴⁴ are receptors involved in β -VLDL uptake. Therefore, we studied the effect of IL-9 on the expression of these receptors in RAW cells. RAW cells were cultured in the absence/presence of IL-9 for 16 hours, after which RNA was isolated for quantitative real-time PCR-analysis. LDLr, LRP-1 and SR-BI were expressed in untreated control RAW cells. IL-9 treatment showed a tendency to a 1.28-fold downregulation of LDLr gene expression ($p = 0.06$). LRP-1 and SR-BI expression were significantly downregulated by IL-9, 2.13-fold and 1.89-fold respectively (**Fig. 2A-C**). In addition, Western Blot analysis confirmed that SR-BI protein expression was significantly 1.54-fold decreased by IL-9 treatment as determined by Western Blot analysis ($p < 0.05$, **Fig. 2D**). The expression of the VLDLr was not detectable in both conditions (data not shown), suggesting a very low expression of VLDLr in macrophages.




Fig. 2: Effect of IL-9 on mRNA expression of LDLr, LRP-1 and SR-BI. RAW cells were cultured for 16 hours in the absence or presence of IL-9, after which RNA or protein was isolated. Quantitative real-time PCR analysis was used to determine the mRNA expression of **A** LDLr, **B** LRP-1 and **C** SR-BI. Values are expressed as mean $\pm$ SEM of relative mRNA expression compared to housekeeping gene expression (arbitrary units). Significant differences between control cells and cells treated with IL-9: * $p < 0.05$. **D** Western blot of SR-BI

Cholesterol efflux

We investigated whether the effect of IL-9 on foam cell formation was due to a stimulatory effect on cholesterol efflux, because foam cell formation can be regarded as an imbalance in cholesterol homeostasis²⁰. First, RAW cells were loaded with [³H]cholesterol, after which they were incubated for 16 hours with medium alone or with medium containing IL-9. Cholesterol efflux was determined using BSA (negative control), apoA-I (ABCA1-

mediated) and HDL (ABCG1-mediated) as cholesterol acceptors. In both control and IL-9 treated cells, cholesterol efflux was 6-7% to BSA and increased significantly to 15-16% when the cells were incubated with apoA-I (**Fig. 3A**). After 24 hours of incubation with HDL, cholesterol efflux reached 39-41% in both groups of cells (**Fig. 3A**). The significantly higher efflux to HDL than to apoA-I is consistent with data obtained with peritoneal macrophages⁴⁵. However, no differences were observed between the efflux of cholesterol from control cells and from cells treated with IL-9 at all conditions (**Fig. 3A**). Quantitative real-time PCR-analysis indicated that mRNA of ABCA1 and ABCG1 was expressed in RAW cells (**Fig. 3B/C**) probably mediating the efflux to respectively apoA-I and HDL. In agreement with the cholesterol efflux study, IL-9 had no significant effect on the mRNA expression of ABCA1 and ABCG1 (**Fig. 3B/C**).




Fig. 3: Effect of IL-9 on cholesterol efflux. **A** RAW cells were loaded with ³H-cholesterol for 24 hours at 37°C. Subsequently, cells were cultured in presence or absence of IL-9 for 24 hours. Cholesterol efflux was induced by incubating the cells for 24 hours with culture medium containing BSA or supplemented with apoA-I or HDL. Values are expressed as mean±SEM of % radioactivity in media compared to radioactivity in both media and cells. Significant differences between control cells and cells treated with IL-9: * p<0.05. Significant differences between cells incubated with 2% BSA and cells incubated with apoA-I or HDL: # p<0.05 and ## p<0.01. **B/C** RAW cells were cultured for 16 hours in the absence or presence of IL-9, after which RNA was isolated. Quantitative real-time PCR analysis was used to determine the mRNA expression of **B** ABCA1 and **C** ABCG1. Values are expressed as mean±SEM of relative mRNA expression compared to housekeeping gene expression (arbitrary units).

Effect on TGFβ1, SREBP-1 and SREBP-2

IL-9 is able to stimulate TGFβ1-production in LPS stimulated monocytes¹⁵ and TGFβ1, in turn, can inhibit foam cell formation^{33,34}. Therefore, we determined whether the effect of IL-9 on foam cell formation is mediated by induction of TGFβ1 expression in RAW cells. However, IL-9 did not affect the TGFβ1 expression in RAW cells (**Fig. 4A**) and the inhibitory effect of IL-9 on foam cell formation can not be explained by a stimulatory effect on TGFβ1.

Transcription factors sterol regulatory element binding protein (SREBP)-1 and SREBP-2 are involved in intracellular cholesterol homeostasis. We determined the expression of these transcription factors upon IL-9 treatment. The expression of SREBP-1 and SREBP-2 were significantly decreased by IL-9 treatment, 1.75-fold and 2.08-fold respectively (**Fig. 4B/C**). The downregulation of SREBP-1 and SREBP-2 was confirmed at protein level by Western Blotting (p<0.05, **Fig. 4D/E**)




Fig. 4: Effect of IL-9 on TGFβ1, SREBP-1 and SREBP-2. RAW cells were cultured for 16 hours in the absence or presence of IL-9, after which RNA or protein was isolated. Quantitative real-time PCR analysis was used to determine the mRNA expression of **A** TGFβ1, **B** SREBP-1 and **C** SREBP-2. Values are expressed as mean±SEM of relative mRNA expression compared to housekeeping gene expression (arbitrary units). Significant differences between control cells and cells treated with IL-9: ** $p < 0.01$ and *** $p < 0.001$. **D** Western blot of SREBP-1. **E** Western blot of SREBP-2

Effect on PPARα, PPARγ and PPARδ

Nuclear receptors such as PPARs are also able to influence genes which are important for foam cell formation³⁰. Therefore, we determined whether IL-9 had an effect on the expression of PPARα, PPARγ and PPARδ in RAW cells. PPARγ expression was not detectable in our system, suggesting that PPARγ expression was very low in RAW cells (data not shown). The expression of PPARδ was not affected by IL-9 (**Fig. 5A**), whereas IL-9 was able to significantly increase PPARα expression 4-fold (**Fig. 5B**).




Fig. 5: Effect of IL-9 on PPARα and PPARδ. RAW cells were cultured for 16 hours in the absence or presence of IL-9, after which RNA was isolated. Quantitative real-time PCR analysis was used to determine the mRNA expression of **A** PPARδ and **B** PPARα. Values are expressed as mean±SEM of relative mRNA expression compared to housekeeping gene expression (arbitrary units). Significant differences between control cells and cells treated with IL-9: * $p < 0.05$.

DISCUSSION

According to our previous studies in LDLr deficient mice, IL-9 is proposed to have a therapeutic potential in atherosclerosis due to its ability to inhibit atherogenesis¹⁶. During the development of atherosclerosis, macrophages play a central role in both inflammation and lipid deposition. It is already known that IL-9 is able to influence inflammation by inhibiting oxidative burst and cytokine release in both LPS stimulated monocytes¹⁵ and alveolar macrophages³. On the other hand, the relation between inflammatory mediators such as IL-9 and foam cell formation in the macrophage remains poorly understood. We therefore investigated the effect of IL-9 on macrophage foam cell formation.

In addition to modified lipoproteins, β -VLDL, a lipoprotein that is naturally induced upon cholesterol-rich feeding in animals⁴⁰, is able to induce foam cell formation in mouse peritoneal macrophages *in vitro*²¹. Until now, only one study has been performed in which β -VLDL was used to induce cholesterol ester accumulation in murine macrophage RAW cells³¹. In our experiments, the induction of foam cells by incubating RAW cells with β -VLDL was clearly visible. β -VLDL in a concentration between 25 and 100 μ g/ml caused a lipid area between 2.3% and 9.5% in RAW cells after 24 hours. Because of its pathological relevance in LDLr deficient mice, we used β -VLDL to study the effect of IL-9 on foam cell formation.

Pre-incubation of RAW cells with IL-9 resulted in a 2-fold reduction in foam cell formation induced by β -VLDL in a concentration between 25 and 100 μ g/ml. The protective effect of the anti-inflammatory IL-9 is in line with our earlier results in peritoneal macrophages derived from LDLr deficient mice¹⁶ and with the induction of foam cell formation by pro-inflammatory mediators. LPS³¹ and TNF- α ³² are examples of pro-inflammatory mediators that stimulate foam cell formation either by downregulating mediators of efflux (LPS)⁴⁶ or by upregulating receptors for uptake of modified lipoproteins (TNF- α)^{32,47}. Like IL-9, the anti-inflammatory TGF β 1 is able to inhibit foam cell formation. TGF β 1 mediated this effect through inhibition of macrophage LPL, inhibition of the expression and activity of the LDLr, SR-AI/II and CD36 and enhancement of macrophage cholesterol efflux³³. Moreover, TGF β 1 is able to inhibit downregulation of ABCA1 expression and macrophage cholesterol efflux induced by IFN- γ ³⁴.

Although IL-9 induces TGF β 1 in LPS stimulated human monocytes leading to inhibition of oxidative burst and TNF- α release¹⁵, TGF β 1 expression in RAW cells was not affected by IL-9 in our study. Therefore, the inhibitory effect of IL-9 on foam cell formation is unlikely to be mediated by TGF β 1. IL-10, another anti-inflammatory cytokine, shares the ability with IL-9 to protect against atherogenesis^{48,49}. However, unlike IL-9, IL-10 enhances the formation of foam cells induced by oxLDL³⁵. It has to be taken into account that oxLDL, in contrast to β -VLDL, is able to induce apoptosis^{50,51} and IL-10 exerted its foam cell promoting effect by inhibiting oxLDL induced apoptosis rather than by affecting macrophage lipid uptake or efflux³⁵.

We investigated the potential mechanism of the IL-9 induced inhibition of β -VLDL induced foam cell formation. Various macrophage receptors capable of binding and taking up β -VLDL are identified, including LDLr, LRP-1, VLDLr and SR-BI⁴¹⁻⁴⁴ of which LDLr is the major candidate. We studied the

effect of IL-9 on the expression of these receptors and indicated that IL-9 had a tendency to decrease the expression of the LDLr (1.28-fold, $p=0.06$) and clearly decreased the expression of LRP-1 and SR-BI in RAW cells, 2.13-fold and 1.89-fold respectively. Together the reduced expression of receptors for β -VLDL will lead to a lower uptake of β -VLDL, which can at least partly explain the inhibitory effect of IL-9 on foam cell formation. Downregulation of LRP-1 and SR-BI mRNA expression by IL-9 can explain why IL-9 was also able to inhibit β -VLDL induced foam cell formation of peritoneal macrophages deficient in LDLr¹⁶.

SREBPs are known to regulate the expression of the LDLr in various cell types. In a human renal mesangial cell line, the pro-inflammatory cytokines TNF- α and IL-1 β were able to induce LDLr expression by upregulation of SREBP-1⁵², suggesting a link between inflammation, SREBPs and LDLr expression. In contrast to TNF- α , IL-9 reduced the expression of SREBP-1 in RAW cells correlating with the observed IL-9 induced downregulation of the LDLr. SREBP-2 is possibly involved in the regulation of the expression of LRP-1, because LDL induced LRP-1 upregulation is reduced by an inhibitor of SREBP-2 in human vascular smooth muscle cells⁵³. In our experiments, IL-9 was able to reduce SREBP-2 expression, which coincided with the downregulation of LRP-1 in RAW cells. However, PPAR γ has been shown to regulate LRP-1 gene expression and function in adipocytes⁵⁴. Unfortunately, we were not able to detect PPAR γ in our experimental set-up.

SR-BI promotes a bi-directional flux of cholesterol between cells and HDL⁵⁵ and although we observed a downregulation of its expression by IL-9 in RAW cells, we did not observe an effect of IL-9 on cholesterol efflux either to HDL or apoA-I, suggesting that SR-BI mediated efflux is not active under our conditions. SR-BI appears to play a dual role in the development of atherosclerosis: SR-BI induces the development of small fatty streak lesions, while it protects against the development of more advanced atherosclerotic lesions⁵⁶. We determined the effect of IL-9 on the expression of SR-BI in RAW cells that were not loaded with cholesterol and therefore in a situation in which SR-BI probably functions as a mediator of cholesterol uptake rather than as a mediator of cholesterol efflux.

Recently, it was reported that liver X receptor (LXR)/retinoid X receptor (RXR) treatment of macrophages lacking ABCG1 failed to stimulate cholesterol efflux to HDL, whereas in wild type macrophage cholesterol efflux was increased by this treatment²⁵. Together with other studies^{24,26}, this suggests that ABCG1 is a key gene involved in cholesterol efflux from the macrophage to HDL. We observed no effect of IL-9 on the expression of ABCG1 in RAW cells, explaining why cholesterol efflux to HDL was not affected by IL-9 in our study in spite of a reduced SR-BI expression.

Cholesterol efflux from macrophages to lipid-poor apoA-I is primarily regulated by ABCA1⁵⁷⁻⁵⁹. The expression of ABCA1 in vascular endothelial cells is downregulated by activation of SREBP-2⁶⁰. Although IL-9 reduced the expression of SREBP-2 in RAW cells, the expression of ABCA1 in these cells was not affected by IL-9. In agreement with the unchanged expression of ABCA1, cholesterol efflux to apoA-I was not affected by IL-9 in our studies.

Several studies show the effects of PPARs on foam cell formation and the development of atherosclerosis. PPAR α is described to protect against foam cell formation by inducing cholesterol efflux. However, Li et al.³⁰ found that PPAR α agonists reduced atherosclerosis and foam cell formation, but they did not observe an effect on the expression of ABCA1 nor on the expression of ABCG1. We found that treatment of RAW cells with IL-9 led to a 4-fold increase in PPAR α expression. In agreement with Li et al, we did not find any changes in the expression of ABCA1 and ABCG1 upon IL-9 treatment. PPAR γ and PPAR δ can also effect cholesterol homeostasis^{61,62}, but changes in expression of these nuclear receptors by IL-9-treatment were not observed in RAW cells.

In conclusion, IL-9 is able to reduce the expression of receptors for β -VLDL uptake, to induce the nuclear receptor PPAR α and to reduce the transcription factors SREBP-1 and SREBP-2, resulting in reduced foam cell formation. Although IL-9 is considered a risk factor for the development of asthma and some parasitic infections, it shows beneficial properties by protecting against bacterial and nematode infections and atherosclerosis. Our data provide the first evidence for a direct effect of IL-9 on the gene expression of key players in foam cell formation providing a possible mechanism for the anti-atherogenic effect of IL-9.

ACKNOWLEDGEMENTS

This research was supported by the Netherlands Heart Foundation (grants 2001B164 and 2000T40).

REFERENCES

1. Uyttenhove C, Simpson RJ and Van Snick J (1988) Functional and structural characterization of P40, a mouse glycoprotein with T-cell growth factor activity. *Proc Natl Acad Sci U S A*. **85**: 6934-6938.
2. Demoulin JB and Renauld JC (1998) Interleukin 9 and its receptor: an overview of structure and function. *Int Rev Immunol*. **16**: 345-364.
3. Pilette C, Ouadrhiri Y, Van Snick J, Renauld JC, Staquet P, Vaerman JP and Sibille Y (2002) Oxidative burst in lipopolysaccharide-activated human alveolar macrophages is inhibited by interleukin-9. *Eur Respir J*. **20**: 1198-1205.
4. Nicolaides NC, Holroyd KJ, Ewart SL, Eleff SM, Kiser MB, Dragwa CR, Sullivan CD, Grasso L, Zhang LY, Messler CJ, Zhou T, Kleeberger SR, Buetow KH and Levitt RC (1997) Interleukin 9: a candidate gene for asthma. *Proc Natl Acad Sci U S A*. **94**: 13175-13180.
5. Temann UA, Geba GP, Rankin JA and Flavell RA (1998) Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. *J Exp Med*. **188**: 1307-1320.
6. McLane MP, Haczku A, van de Rijn M, Weiss C, Ferrante V, MacDonald D, Renauld JC, Nicolaides NC, Holroyd KJ and Levitt RC (1998) Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. *Am J Respir Cell Mol Biol*. **19**: 713-720.
7. Kung TT, Luo B, Crawley Y, Garlisi CG, Devito K, Minnicozzi M, Egan RW, Kreutner W and Chapman RW (2001) Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. *Am J Respir Cell Mol Biol*. **25**: 600-605.

8. Cheng G, Arima M, Honda K, Hirata H, Eda F, Yoshida N, Fukushima F, Ishii Y and Fukuda T (2002) Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. *Am J Respir Crit Care Med.* **166**: 409-416.
9. McMillan SJ, Bishop B, Townsend MJ, McKenzie AN and Lloyd CM (2002) The absence of interleukin 9 does not affect the development of allergen-induced pulmonary inflammation nor airway hyperreactivity. *J Exp Med.* **195**: 51-57.
10. Arendse B, Van Snick J and Brombacher F (2005) IL-9 is a susceptibility factor in Leishmania major infection by promoting detrimental Th2/type 2 responses. *J Immunol.* **174**: 2205-2211.
11. Fallon PG, Smith P, Richardson EJ, Jones FJ, Faulkner HC, Van Snick J, Renauld JC, Grecis RK and Dunne DW (2000) Expression of interleukin-9 leads to Th2 cytokine-dominated responses and fatal enteropathy in mice with chronic Schistosoma mansoni infections. *Infect Immun.* **68**: 6005-6011.
12. Grohmann U, Van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, Renauld JC, Fioretti MC and Puccetti P (2000) IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. *J Immunol.* **164**: 4197-4203.
13. Faulkner H, Humphreys N, Renauld JC, Van Snick J and Grecis R (1997) Interleukin-9 is involved in host protective immunity to intestinal nematode infection. *Eur J Immunol.* **27**: 2536-2540.
14. Khan WJ, Richard M, Akiho H, Blennerhasset PA, Humphreys NE, Grecis RK, Van Snick J and Collins SM (2003) Modulation of intestinal muscle contraction by interleukin-9 (IL-9) or IL-9 neutralization: correlation with worm expulsion in murine nematode infections. *Infect Immun.* **71**: 2430-2438.
15. Pilette C, Ouadhriri Y, Van Snick J, Renauld JC, Staquet P, Vaerman JP and Sibille Y (2002) IL-9 inhibits oxidative burst and TNF-alpha release in lipopolysaccharide-stimulated human monocytes through TGF-beta. *J Immunol.* **168**: 4103-4111.
16. Von Der Thusen JH, Stitzinger M, De Vos P, Van Berkel TJ, Biessen EA, Van Snick J and Kuiper J (2006) The role of IL-9 in atherosclerosis and its application in the prevention of atherogenesis. **submitted for publication**
17. Lusis AJ (2000) Atherosclerosis. *Nature.* **407**: 233-241.
18. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med.* **352**: 1685-1695.
19. Quehenberger O (2005) Thematic review series: the immune system and atherogenesis. Molecular mechanisms regulating monocyte recruitment in atherosclerosis. *J Lipid Res.* **46**: 1582-1590.
20. Linton MF and Fazio S (2003) Macrophages, inflammation, and atherosclerosis. *Int J Obes Relat Metab Disord.* **27 Suppl 3**: S35-40.
21. Goldstein JL, Ho YK, Brown MS, Innerarity TL and Mahley RW (1980) Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine beta-very low density lipoproteins. *J Biol Chem.* **255**: 1839-1848.
22. Brown MS, Goldstein JL, Krieger M, Ho YK and Anderson RG (1979) Reversible accumulation of cholesteryl esters in macrophages incubated with acetylated lipoproteins. *J Cell Biol.* **82**: 597-613.
23. Arai H, Kita T, Yokode M, Narumiya S and Kawai C (1989) Multiple receptors for modified low density lipoproteins in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized low density lipoproteins. *Biochem Biophys Res Commun.* **159**: 1375-1382.
24. Wang N, Lan D, Chen W, Matsuura F and Tall AR (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. *Proc Natl Acad Sci U S A.* **101**: 9774-9779.
25. Kennedy MA, Barrera GC, Nakamura K, Baldan A, Tarr P, Fishbein MC, Frank J, Francone OL and Edwards PA (2005) ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. *Cell Metab.* **1**: 121-131.
26. Klucken J, Buchler C, Orso E, Kaminski WE, Porsch-Ozcurumez M, Liebisch G, Kapinsky M, Diederich W, Drobnik W, Dean M, Allikmets R and Schmitz G (2000) ABCG1 (ABC8), the human homolog of the Drosophila white gene, is a regulator of macrophage cholesterol and phospholipid transport. *Proc Natl Acad Sci U S A.* **97**: 817-822.

27. Wang N, Silver DL, Costet P and Tall AR (2000) Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. *J Biol Chem.* **275**: 33053-33058.
28. Wang N, Silver DL, Thiele C and Tall AR (2001) ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. *J Biol Chem.* **276**: 23742-23747.
29. Jian B, de la Llera-Moya M, Ji Y, Wang N, Phillips MC, Swaney JB, Tall AR and Rothblat GH (1998) Scavenger receptor class B type I as a mediator of cellular cholesterol efflux to lipoproteins and phospholipid acceptors. *J Biol Chem.* **273**: 5599-5606.
30. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Villedor AF, Davis RA, Willson TM, Witztum JL, Palinski W and Glass CK (2004) Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. *J Clin Invest.* **114**: 1564-1576.
31. Funk JL, Feingold KR, Moser AH and Grunfeld C (1993) Lipopolysaccharide stimulation of RAW 264.7 macrophages induces lipid accumulation and foam cell formation. *Atherosclerosis.* **98**: 67-82.
32. Hsu HY and Twu YC (2000) Tumor necrosis factor-alpha -mediated protein kinases in regulation of scavenger receptor and foam cell formation on macrophage. *J Biol Chem.* **275**: 41035-41048.
33. Arghmann CA, Van Den Diepstraten CH, Sawyez CG, Edwards JY, Hegele RA, Wolfe BM and Huff MW (2001) Transforming growth factor-beta1 inhibits macrophage cholesteryl ester accumulation induced by native and oxidized VLDL remnants. *Arterioscler Thromb Vasc Biol.* **21**: 2011-2018.
34. Panousis CG, Evans G and Zuckerman SH (2001) TGF-beta increases cholesterol efflux and ABC-1 expression in macrophage-derived foam cells: opposing the effects of IFN-gamma. *J Lipid Res.* **42**: 856-863.
35. Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thusen JH, Muller F, Heimli H, Tonstad S, Hall C, Froland SS, Biessen EA, Damas JK and Aukrust P (2005) Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. *J Lipid Res.* **46**: 211-219.
36. Redgrave TG, Roberts DC and West CE (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. *Anal Biochem.* **65**: 42-49.
37. Van Eck M, Herijgers N, Yates J, Pearce NJ, Hoogerbrugge PM, Groot PH and Van Berkel TJ (1997) Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. *Arterioscler Thromb Vasc Biol.* **17**: 3117-3126.
38. Druetz C, Coulie P, Uyttenhove C and Van Snick J (1990) Functional and biochemical characterization of mouse P40/IL-9 receptors. *J Immunol.* **145**: 2494-2499.
39. Hoekstra M, Kruijt JK, Van Eck M and Van Berkel TJ (2003) Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. *J Biol Chem.* **278**: 25448-25453.
40. Mahley RW, Innerarity TL, Brown MS, Ho YK and Goldstein JL (1980) Cholesteryl ester synthesis in macrophages: stimulation by beta-very low density lipoproteins from cholesterol-fed animals of several species. *J Lipid Res.* **21**: 970-980.
41. Perrey S, Ishibashi S, Kitamine T, Osuga J, Yagyu H, Chen Z, Shionoiri F, Iizuka Y, Yahagi N, Tamura Y, Ohashi K, Harada K, Gotoda T and Yamada N (2001) The LDL receptor is the major pathway for beta-VLDL uptake by mouse peritoneal macrophages. *Atherosclerosis.* **154**: 51-60.
42. Qu S, Wu F, Tian J, Li Y, Wang Y and Zong Y (2004) Role of VLDL receptor in the process of foam cell formation. *J Huazhong Univ Sci Technolog Med Sci.* **24**: 1-4, 8.
43. Kuchenhoff A, Harrach B and Robenek H (1994) Beta-VLDL. A naturally occurring ligand for LRP with physiological importance. *Ann N Y Acad Sci.* **737**: 465-467.
44. Herijgers N, Van Eck M, Korpelaar SJ, Hoogerbrugge PM and Van Berkel TJ (2000) Relative importance of the LDL receptor and scavenger receptor class B in the beta-VLDL-induced uptake and accumulation of cholesteryl esters by peritoneal macrophages. *J Lipid Res.* **41**: 1163-1171.
45. Van Eck M, Singaraja RR, Ye D, Hildebrand RB, James ER, Hayden MR and Van Berkel TJ (2006) Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. *Arterioscler Thromb Vasc Biol.* **26**: 929-934.

46. Baranova I, Vishnyakova T, Bocharov A, Chen Z, Remaley AT, Stonik J, Eggerman TL and Patterson AP (2002) Lipopolysaccharide down regulates both scavenger receptor B1 and ATP binding cassette transporter A1 in RAW cells. *Infect Immun.* **70**: 2995-3003.
47. Moriwaki H, Kume N, Kataoka H, Murase T, Nishi E, Sawamura T, Masaki T and Kita T (1998) Expression of lectin-like oxidized low density lipoprotein receptor-1 in human and murine macrophages: upregulated expression by TNF-alpha. *FEBS Lett.* **440**: 29-32.
48. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Esposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D and Tedgui A (1999) Protective role of interleukin-10 in atherosclerosis. *Circ Res.* **85**: e17-24.
49. Von Der Thusen JH, Kuiper J, Fekkes ML, De Vos P, Van Berkel TJ and Biessen EA (2001) Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr^{-/-} mice. *Faseb J.* **15**: 2730-2732.
50. Asmis R and Begley JG (2003) Oxidized LDL promotes peroxide-mediated mitochondrial dysfunction and cell death in human macrophages: a caspase-3-independent pathway. *Circ Res.* **92**: e20-29.
51. Panini SR, Yang L, Rusinol AE, Sinensky MS, Bonventre JV and Leslie CC (2001) Arachidonate metabolism and the signaling pathway of induction of apoptosis by oxidized LDL/oxysterol. *J Lipid Res.* **42**: 1678-1686.
52. Ruan XZ, Varghese Z, Powis SH and Moorhead JF (2001) Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. *Kidney Int.* **60**: 1716-1725.
53. Llorente-Cortes V, Otero-Vinas M, Sanchez S, Rodriguez C and Badimon L (2002) Low-density lipoprotein upregulates low-density lipoprotein receptor-related protein expression in vascular smooth muscle cells: possible involvement of sterol regulatory element binding protein-2-dependent mechanism. *Circulation.* **106**: 3104-3110.
54. Gauthier A, Vassiliou G, Benoist F and McPherson R (2003) Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. *J Biol Chem.* **278**: 11945-11953.
55. Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, Rothblat GH, Swaney JB and Tall AR (1997) Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. *J Biol Chem.* **272**: 20982-20985.
56. Van Eck M, Bos IS, Hildebrand RB, Van Rij BT and Van Berkel TJ (2004) Dual role for scavenger receptor class B, type I on bone marrow-derived cells in atherosclerotic lesion development. *Am J Pathol.* **165**: 785-794.
57. Oram JF, Lawn RM, Garvin MR and Wade DP (2000) ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. *J Biol Chem.* **275**: 34508-34511.
58. Oram JF and Heinecke JW (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. *Physiol Rev.* **85**: 1343-1372.
59. Attie AD, Kastelein JP and Hayden MR (2001) Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. *J Lipid Res.* **42**: 1717-1726.
60. Zeng L, Liao H, Liu Y, Lee TS, Zhu M, Wang X, Stemerman MB, Zhu Y and Shyy JY (2004) Sterol-responsive element-binding protein (SREBP) 2 down-regulates ATP-binding cassette transporter A1 in vascular endothelial cells: a novel role of SREBP in regulating cholesterol metabolism. *J Biol Chem.* **279**: 48801-48807.
61. Zhang L and Chawla A (2004) Role of PPARgamma in macrophage biology and atherosclerosis. *Trends Endocrinol Metab.* **15**: 500-505.
62. Bedu E, Wahli W and Desvergne B (2005) Peroxisome proliferator-activated receptor beta/delta as a therapeutic target for metabolic diseases. *Expert Opin Ther Targets.* **9**: 861-873.
